CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases...
Liver MetastasesThis is an open label, fixed dose, phase Ib trial of anti-CEA CAR-T cell infusions delivered via the hepatic artery or splenic vein using the Surefire Infusion System (SIS) for patients with CEA-expressing liver metastases or pancreas cancer.
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer,...
Breast CancerNon-small Cell Lung Cancer2 moreThe main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain.
Phase I Study on VEGF Vaccination in Metastatic Solid Tumors
Metastatic CancerThe primary objectives of this study are to investigate the safety and tolerability profile of the therapeutic vaccine hVEGF26-104/RFASE and to determine the effective dose of hVEGF26-104/RFASE required to neutralize VEGF in serum, defined as a VEGF level below 9,0 pg/mL.
Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets
Bone MetastasesBreast Cancer1 moreIn patients with cancer induced bone pain, addition of Syndros will improve pain relief and decrease opioid requirement.
A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement...
Partial Seizures With or Without Secondary GeneralizationEpilepsyThe purpose of the study is to evaluate the safety and tolerability of intravenous (iv) brivaracetam (BRV) as adjunctive therapy administered as a replacement for oral BRV at doses ranging from BRV 50 mg/day to 200 mg/day in Japanese subjects >=16 years of age with partial seizures with or without secondary generalization and to evaluate the partial seizure frequency after switching from oral administration to iv BRV.
New Therapeutic Approach in Upper Limb Lymphedema Secondary to Breast Cancer: Activity-oriented...
Breast Cancer LymphedemaPost-Mastectomy Secondary LymphedemaThis study evaluates the effectiveness of an experimental proposal therapy for upper limb lymphedema secondary to breast called Activity-oriented proprioceptive antiedema therapy (TAPA) facing the consensual gold standard treatment, the complete decongestive therapy. TAPA consists in: Health education / patient empowerment. Neurodynamic activities oriented to Activities of Daily Living (ADL). Proprioceptive neuromuscular facilitation exercises oriented to ADL. Self-adherent self-adhesive antiedema of low compression. Half of patients will receive TAPA treatment while the other half will receive CDT standard treatment.
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release...
Secondary Hyperparathyroidism Due to Renal CausesVitamin D Insufficiency2 moreAn Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral...
Advanced Metastatic CancerAdvanced Prostate CancerThis is an open-label, exploratory study to evaluate nivolumab with or without ipilimumab based on percentage of tumoral CD8 cells at the time of treatment in participants with varying advanced solid tumors. Participants who have a tumor with ≥ 15% CD8 cells (classified as CD8 high) will receive nivolumab monotherapy, and participants who have a tumor with < 15% CD8 cells (classified as CD8 low) will receive ipilimumab in combination with nivolumab.
Phase 3 Study of SK-1403
Secondary HyperparathyroidismTo evaluate the efficacy and safety of treatment with SK-1403 for 24 weeks in patients with secondary hyperparathyroidism on maintenance hemodialysis.
Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia
Secondary HyperparathyroidismThe purpose of this study is to evaluate the efficacy and the safety of KHK7580 orally administered once daily for 52 weeks compared to cinacalcet hydrochloride as an active control in subjects with secondary hyperparathyroidism receiving hemodialysis in China, Korea, Hong Kong and Taiwan.